Teladoc Health (TDOC) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Teladoc Health published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Teladoc Health reports in thousands of dollars. Figures here are converted to millions and rounded to one decimal.
• Q3 2025 results included a non-cash goodwill impairment charge of $12.6 million in the Integrated Care segment, tied to the Telecare Australia acquisition.

Source: Teladoc Health Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Teladoc Health splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Teladoc Health's Integrated Care revenue was $399 million in Q3 2026, up 2% from $390 million in Q3 2025, 66% of total revenue.
• Teladoc Health's BetterHelp revenue was $207 million in Q3 2026, down 13% from $237 million in Q3 2025, 34% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

The first three lines are Teladoc Health's outlook for the fourth quarter of 2026. The last is its full-year 2026 revenue range. Teladoc Health does not report an adjusted EPS figure, so its outlook gives a GAAP net loss per share range.

In its Q3 2026 release, Teladoc Health said:

“Revenue $569-$615 million”

“Adjusted EBITDA $74-$100 million”

“Net loss per share ($0.23) - ($0.03)”

“Revenue $2,395-$2,441 million”

Source: Teladoc Health Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the TDOC forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and net loss per share (basic and diluted), each as first reported in that quarter's release, converted from thousands to millions.

We do not hold a confirmed date for Teladoc Health's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Teladoc Health has two segments. Integrated Care, which sells virtual general medical, specialty, chronic condition and mental health services mainly through health plans and employers, had revenue of $398.5 million in Q3 2026, up 2%. BetterHelp, its direct-to-consumer virtual therapy business, had revenue of $206.6 million, down 13%. Total revenue fell 3% to $605.1 million from $626.4 million. (Teladoc Health Q3 2026 release, Oct 28, 2026)

Inside BetterHelp, revenue from users paying out of pocket (Consumer and Other) fell 25% to $174.5 million, while Insurance Covered Services grew to $32.1 million from $3.7 million. Teladoc Health attributed the segment decline to actions to prioritize Insurance Covered Services and the continuing decline in users paying directly out of pocket. BetterHelp Paying Users averaged 0.336 million, down 12% from 0.382 million. (Teladoc Health Q3 2026 release, Oct 28, 2026; Teladoc Health Form 10-Q, Q3 2026, Oct 29, 2026)

By type, access fees revenue fell 10% to $466.7 million, while other revenue, mostly visit fees and hospital telehealth sales, rose 31% to $138.4 million. By geography, U.S. revenue fell 4% to $489.2 million and International revenue fell 1% to $115.9 million. (Teladoc Health Q3 2026 release, Oct 28, 2026; Teladoc Health Form 10-Q, Q3 2026, Oct 29, 2026)

Integrated Care revenue is concentrated in a few large clients. In Q3 2026 one Integrated Care customer accounted for about $68.1 million of consolidated revenue, and the five largest clients accounted for 33% of Integrated Care segment revenue over the first nine months of 2026, against 31% a year earlier. (Teladoc Health Form 10-Q, Q3 2026, Oct 29, 2026)

Teladoc Health reported a net loss of $26.9 million, or $0.15 per share, in Q3 2026, against $49.5 million, or $0.28 per share, a year earlier. It does not publish an adjusted EPS figure; its main non-GAAP profit measure is adjusted EBITDA, which rose 14% to $79.4 million. (Teladoc Health Q3 2026 release, Oct 28, 2026)

The largest non-cash item in the loss is amortization of intangibles, $88.3 million or $0.49 per share pre-tax. The quarter also carried $11.6 million of stock-based compensation, down from $17.0 million, and $4.4 million of restructuring costs. The year-ago quarter included a $12.6 million goodwill impairment charge. (Teladoc Health Q3 2026 release, Oct 28, 2026)

Advertising and marketing expense fell to $124.0 million from $168.0 million, a decrease of 26%, which the 10-Q attributes mainly to lower digital and media advertising as BetterHelp shifted toward Insurance Covered Services. Weighted-average shares rose to 181,876,281 from 176,934,781. (Teladoc Health Form 10-Q, Q3 2026, Oct 29, 2026; Teladoc Health Q3 2026 release, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Teladoc Health gives a quarterly and a full-year outlook in its release. For Q4 2026 it expects revenue of $569 - $615 million, adjusted EBITDA of $74 - $100 million and a net loss per share of ($0.23) - ($0.03). For the full year 2026 it expects revenue of $2,395 - $2,441 million, adjusted EBITDA of $277 - $303 million and free cash flow of $135 - $165 million. (Teladoc Health Q3 2026 release, Oct 28, 2026)

By segment, Teladoc Health's full-year outlook calls for Integrated Care revenue growth of 1.1% - 2.1% and BetterHelp revenue growth of (16.1%) - (12.9%), with U.S. Integrated Care Members of 99.5 - 100.5 million. (Teladoc Health Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover Teladoc Health, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Teladoc Health's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TDOC is on is TDOC a buy or a sell?, what analysts expect next is on the TDOC forecast, and what the company does is on the Teladoc Health (TDOC) stock page.

Every number on this page can be traced to a document Teladoc Health published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.